anti-alpha-v/beta-3 mAb (SmithKline Beecham)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-alpha-v/beta-3 mAb (SmithKline Beecham)

Drug Alias Nameanti-vitronectin mAb (SmithKline Beecham)anti-alpha-v/beta-5 mAb (SmithKline Beecham)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists

TargetsIntegrin alpha-V/beta-3

Therapy Area/IndicationsCoronary RestenosisArthritis, RheumatoidNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesSmithkline Beecham Pharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSmithkline Beecham Pharmaceuticals

Active IndicationsN/A

Inactive IndicationsCoronary RestenosisArthritis, RheumatoidNeoplasms

Other Information

ATC CodeN/A